aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower – Hagens Berman

Core Viewpoint - aTyr Pharma, Inc. experienced a dramatic decline in share price, dropping over 80% after failing to meet the primary endpoint in its late-stage study of efzofitimod for pulmonary sarcoidosis treatment [1][7]. Company Summary - On September 15, 2025, aTyr announced that its EFZO-FIT trial did not achieve statistical significance in steroid reduction after a year of tapering, leading to a significant market reaction [7]. - The company had previously assured investors that its Phase 2 data was among the best seen by experts and highlighted a multi-billion-dollar market opportunity for efzofitimod [6]. Investigation Summary - Following the market reaction, Hagens Berman, a national shareholders rights firm, initiated an investigation into whether aTyr misled investors regarding its Phase 2 data and Phase 3 trial design [2][5]. - The investigation is focused on the accuracy of aTyr's disclosures about the quality of its Phase 2 data and the design of the EFZO-FIT trial [5]. Market Reaction - The announcement of the topline results led to a flood of analyst downgrades and a catastrophic drop in aTyr's share price, reflecting investor disappointment and loss of confidence [7].